Bernd Giebel studied biology in Cologne and received his PhD in 1996. 1999 he moved to the Heinrich-Heine-University of Düsseldorf, to work with human hematopoietic stem and progenitor cells. In 2008 he switched to the University Hospital Essen, continued his studies on human somatic stem cells and started to work with EVs in 2009. Setting a focus on mesenchymal stem/stromal cell-derived EVs (MSC-EVs), together with collaboration partners his group demonstrated the therapeutic potential of MSC-EVs in a human GvHD-patient and in different animal models. Coupled to his international success, in 2023, he was appointed as full professor for Translational Extracellular Vesicle Research at the University Hospital Essen.
Research wise, it is his goal to efficiently translate MSC-EVs into the clinics and to set up appropriate quality control platforms. Furthermore, it is his mission to promote national and international EV research. In this context, BG acted as the founding president of the German Society of Extracellular Vesicles (GSEV) from 2017 to 2023. Since 2018, he is co-chairing the exosome working group of the International Society of Gene and Cell Therapy (ISCT) and is part of the scientific advisory board of four SME companies, Innovex Therapeutics, Mursla LTD, PL BioScience and ReNeuron. Furthermore, he is a consultant of FUJIFILM Wako Chemicals Europe GmbH and founding director of Exosla LTD.
Publications:
https://orcid.org/0000-0003-2446-948X
